Pegmolesatide injection | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Company
- Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
- Medicine type
- Chemical medicine
- Therapeutic area
- Kidney diseases
- Indications recorded in the public source
- For anemia caused by chronic kidney disease (CKD), including: (1) adults not receiving dialysis who have not received an erythropoiesis-stimulating agent (ESA); and (2) adults receiving dialysis who are currently treated with a short-acting erythropoietin. Not a substitute for red blood cell transfusion when immediate correction of anemia is required.
- Indication source and scope
- 2026-03-02
- Prescribing-information limitations
- Complete official prescribing information obtained. Mainland China label.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Market-by-market verification pending.
- Insurance classification
- Included in national insurance (Category B)
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance restrictions
- Restricted to anemia due to CKD in: (1) adults not receiving dialysis who have not received an ESA; or (2) adults receiving dialysis who are currently treated with short-acting erythropoietin.
- Insurance period
- 2026-01-01 to 2027-12-31
- Insurance verification notes
- Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.
Sources
- https://www.nmpa.gov.cn/directory/web/nmpa/images/1707039824076019627.pdf
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
- https://cn.hspharm.com/upload/file/2026/07/10/82ac529c75b14c8c86d9106f1288baf5.pdf
Open the interactive record, public price references and discussions